Optimize DeliveryBetter Glycemic Control with Less Insulin

Optimize the Way Insulin is Delivered with V-Go®

V-Go Mimics the Body’s Natural Physiology¹

V-Go is an innovative, all-in-one insulin patch that’s proven to deliver effective outcomes by providing patients with a consistent and continuous basal rate as well as on-demand bolus.^1-4

Efficient Delivery for Better Glycemic Control

Significant and sustained A1c reduction in a broad range of patients with diabetes¹

• Patients with A1c>7.0% at baseline who were sub-optimally controlled on current diabetes therapy¹
• A1c reductions with V-Go were maintained through 6 months¹

Study Design: In a retrospective analysis of an electronic medical records database, patients with uncontrolled diabetes (A1c>7.0%) on previous therapeutic regimens and switched to V-Go were Identified. A total of 153 patients were evaluated. Of these, 86 were on MDI, 45 on basal only, and 22 were insulin naive at baseline.^1,5

Proven to Lower Insulin Requirements

The unique insulin delivery of V-Go significantly lowered basal-bolus requirements²

• In patients who switched to V-Go from MDI, basal and bolus insulin requirements were reduced by 40% and 48%, respectively²
• Patients who switched to V-Go from MDI had an average A1c reduction of 1.2% over 6 months
  (P<0.0001)²

Study Design: Based on a real-world, retrospective analysis of an electronic medical records database. Patients were adults diagnosed with diabetes mellltus, A1c>7.0%, and previously prescribed basal-bolus Insulin therapy.²

V-Go Demonstrated Reductions in Glucose Variability

Optimized delivery with V-Go improved glycemic profiles and time in range⁶

Insulin Delivered by MDI

Insulin Delivered by V-Go

MDI=multiple daily injections; TDD=total daily dose.

• In a 5-week, real-world study using the FreeStyle Libre Pro, patients using V-Go saw a 35% improvement in overall glucose time in range⁶
• Overall glucose time below range decreased from 8.7% to 6.6%⁶

Study Design: A single-center, prospective, pilot study conducted using the FreeStyle Libre Pro in a real-world practice setting was designed to evaluate a percent change in blood glucose time in range (80-140 mg/dL) from baseline in patients switched from MDI to V-Go. Patients were on V-Go for a total of 5 weeks. Seven patients with type 2 diabetes and a stable dose of insulin, with a mean age of 64 years and weight of 226 lb, completed the pilot study.⁶

FreeStyle Libre Pro Is a registered trademark of Abbott Diabetes Care Inc.

Poster presented at the AACE 27th Annual Scientific and Clinical Congress, Boston, MA, May 2018.

References: 1. Lajara R, Nikkel C. Poster: Evaluating the effect of VGo therapy in suboptimally controlled patients with diabetes: a retrospective cohort analysis in a large specialized diabetes system. Presented at: AACE. May 2015. 2. Lajara R, Nikkel C. Poster: Evaluation of real world clinical and pharmacy budget outcomes when switching to a wearable insulin delivery device for insulin administration in patients with suboptimally controlled diabetes. Presented at: ISPOR. May 2017. 3. Rosenfeld CR, Bohannon NJ, et al. The VGo insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control. Endocr Pract. 2012;18(5):660-667. 4. Instructions for Patient Use. Valeritas, Inc. May 2018. 5. Lajara R, Nikkel C. Evaluating the effect of VGo therapy in suboptimally controlled patients with diabetes: a retrospective cohort analysis in a large specialized diabetes system. Abstract #273. May 2015. 6. Parikh S, Dyson J, Nikkel C. Poster: 24 hour wearable basal bolus insulin delivery device improves time in range and treatment satisfaction over multiple daily injections a pilot study. Presented at: AACE. May 2018.